Avanos Medical (AVNS) Depreciation and Depletion (2013 - 2026)

Avanos Medical (AVNS) has 14 years of Depreciation and Depletion data on file, last reported at $5.6 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation and Depletion rose 24.44% year-over-year to $5.6 million; the trailing twelve-month figure through Mar 2026 stood at $20.8 million (up 6.67% YoY), and the FY2025 full-year result was $19.7 million, down 2.96% from the prior year.
• Depreciation and Depletion advanced to $5.6 million in Q1 2026, from $5.4 million in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $5.6 million in Q1 2026 to a low of $4.2 million in Q4 2022.
• A 5-year average of $4.9 million and a median of $4.9 million in 2023 frame the typical range for Depreciation and Depletion.
• Peak annual rise in Depreciation and Depletion reached 500.0% in 2022, while the deepest fall reached 18.52% in 2022.
• Tracing AVNS's Depreciation and Depletion over 5 years: stood at $4.2 million in 2022, then increased by 19.05% to $5.0 million in 2023, then declined by 6.0% to $4.7 million in 2024, then climbed by 14.89% to $5.4 million in 2025, then increased by 3.7% to $5.6 million in 2026.
• Business Quant data shows AVNS's Depreciation and Depletion at $5.6 million in Q1 2026, $5.4 million in Q4 2025, and $5.0 million in Q3 2025.